Cancer Medicine (Apr 2021)

MET transcriptional regulator/serine peptidase inhibitor kunitz type 1 panel operating through HGF/c‐MET axis as a prognostic signature in pan‐cancer

  • Yi Xiang,
  • Bishan Liang,
  • Yu Jiang,
  • Fei Sun,
  • Yang Zhao,
  • Qijing Wu,
  • Xingbin Hu,
  • Yajing Liu,
  • Qiong Huang,
  • Wangjun Liao,
  • Zhiqi Yao,
  • Shaowei Li,
  • Min Shi

DOI
https://doi.org/10.1002/cam4.3834
Journal volume & issue
Vol. 10, no. 7
pp. 2442 – 2460

Abstract

Read online

Abstract Dysregulations in transcription factors (TFs) and their genetic products play important roles in tumorigenesis, tumor progression and metastasis. However, prognostic value of the transcriptional regulatory networks in different cancers has not been investigated in depth. The purpose of our study was to identify and validate a potential predictive signature that combines TFs and their regulatory products in eight solid tumors. We used bioinformatics analysis to identify MET Transcriptional Regulator (MACC1) and Serine Peptidase Inhibitor Kunitz Type 1 (SPINT1) as candidate TFs with the respective downstream regulatory proteins for patient prognosis in pan‐cancer. Subsequent molecular analysis of clinical gastric cancer tissue samples further verified the negative correlation between MACC1 and SPINT1. Further, we showed that mechanistically, MACC1/SPINT1 mediated the pro‐HGF proteolysis and c‐Met phosphorylation in HGF/c‐MET signaling pathway. Kaplan‐Meier plots and receiver operating characteristics analysis revealed that the two‐gene signature combining MACC1 with SPINT1 was effective in predicting survival in all eight cancer cohorts tested. In conclusion, our study clarified the regulatory relationship between MACC1 and SPINT1 in the context of the HGF/c‐MET signaling pathway and determined MACC1/SPINT1 panel as a valuable signature for the prediction of prognosis in patients for multiple solid cancer types.

Keywords